ACAD has done a great job here. As the company have previously said, they only have to repeat P2 trial. This is best outcome for all. The drug gets to those who need it quicker.
The trial will be enrolled quickly. Parents will be lining up to get started.
Becoming a really strong buy now.
Ann: Plans for Phase 3 trial in Rett syndrome, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.11 |
Change
-0.090(0.63%) |
Mkt cap ! $1.750B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.01 | $6.213M | 438.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7700 | $14.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.16 | 3278 | 1 |
View Market Depth
| Last trade - 16.16pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |